Today, Wolfgang Wienand joins Lonza as our CEO. A proven leader, he brings a wealth of expertise and experience from almost two decades in senior leadership positions in the CDMO industry. We are looking forward to working with Wolfgang to meet and exceed the needs of our customers and their patients as we pursue our purpose to enable a healthier world.
Info
At Lonza, we enable A Healthier World by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets. By combining technological insight with world-class manufacturing, scientific expertise and process excellence, we help our customers to deliver new and innovative medicines that help treat a wide range of diseases. While we work in science, there’s no magic formula to how we do it. Our greatest scientific solution is talented people working together, devising commitment and ideas that help our customers to help people. In exchange, we let our people own their careers. Their ideas, big and small, genuinely improve the world. And that’s the kind of work we want to be part of. Our work makes A Meaningful Difference.
- Website
-
http://www.lonza.com
Externer Link zu Lonza
- Branche
- Arzneimittelherstellung
- Größe
- 10.001 Beschäftigte
- Hauptsitz
- Basel
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 1897
- Spezialgebiete
- Pharmaceutical ingredients, Bioscience, Biopharmaceuticals, Custom manufacturing, Biotechnology, Life science ingredients, Nutrition, Cell Therapy, Gene Therapy und Capsules
Orte
Beschäftigte von Lonza
-
Patricia Marinho
Multilingual Marketing | Product | Campaign Manager - Product Launch | Brand Awareness & Lead Generation
-
Peter Harrison
Digital Transformation Director, Operational Improvement, ERP Portfolio planning & Programme Delivery for Finance, HR and Workforce Management…
-
Meredith Brown
-
Sebastian Stenderup
Executive Director - Lonza
Updates
-
Earlier this month, we experienced an incredible few days connecting with you at BIO International. We participated in engaging and insightful discussions, and thank everyone who connected with our team onsite in San Diego. We enjoyed meeting you at our booth, networking with you at our evening reception, and learning more about your biologics, cell and gene therapy and small molecule needs. We look forward to further collaborating to drive positive change in our industry. See you in Boston in 2025! #BIO2024 #biologics #celltherapy #genetherapy #smallmolecules
-
At Lonza, Pride Month is our opportunity to recognize and celebrate the immense value that our diverse colleagues bring to our business. But for us, Pride is more than a month. We are working all the time to create a culture of inclusion and affirmation in which every colleague is safe and supported to be themselves and bring their best. This is how we make a meaningful difference together. #Lonza #PrideMonth #AMeaningfulDifference
-
Join our Lonza experts James Berrie and Eddy BERTHIER for an upcoming webinar, where they will explore innovative strategies and good practices to accelerate the pathway into clinical development for novel biotherapeutics. This session will delve into comprehensive and integrated drug substance/drug product DNA-to-IND programs designed to expedite development across various modalities, including monoclonal antibodies, bispecific antibodies, Fabs, Fc-fusions and non-Fc recombinant proteins. Register today: https://lnkd.in/e2F8X259 📅 Monday, 8 July 🕝 11am EDT / 5pm CET #Lonza #Biologics
-
-
Join us for a must-see webinar on the critical aspects of technology transfer of either biological drug substance or drug product. This session will delve into the strategies and best practices for seamless tech transfer processes, ensuring regulatory compliance, and maintaining product quality and consistency. We will explore real-world case studies highlighting innovative solutions to accelerate clinical tech transfer for drug products, enabling a released clinical batch within five months from kick-off. 📅 Thursday, 11 July, 2024 🕚 11am EDT / 5pm CET Register today: https://lnkd.in/engVg32Y Featured experts: Maolong Liu, Angela Armanni, Andrea Lei Leston #techTransfers #LonzaDPS #sterileDrugProduct #parenteralDrugProduct #drugProduct
-
-
We are pleased to share the June edition of Biologics In Focus, the biologics newsletter from Lonza. Each month we deliver deep analysis of industry trends, expert insights, and an overview of upcoming events - as well as the latest Lonza news and real world customer stories. This month's highlights include: -A webinar from early June on navigating a holistic approach to Container Closure Integrity for biologic drug products -An article from BioPharm International where Lonza experts talk about technological advances that are impacting current aseptic processes and improving time-to-market -A real customer case study from Levicept, discussing their experience with Lonza and how they built a strong relationship to deliver successful partnership outcomes Please do subscribe to ensure you receive the future editions of Biologics In Focus #LonzaBio #pharma #biotechnology #thePeoplePoweringBiologics
-
Now we can help your CMC team overcome the challenge of rising API complexity… Contact us to learn more about Lonza’s AI-Enabled Route Scouting Service. https://lnkd.in/e6xiUpZU #RouteScouting #API #SmallMolecules #WeWorkAsOne
-
"The complexity of drugs and their delivery has been increasing over the past few decades. Combined with a growing prevalence of chronic illnesses, this market evolution is putting more pressure on pharmaceutical manufacturers to develop novel therapies that might also have unique formulation needs.” Peter Droc, Head of Drug Product Services at Lonza, recently shared his thoughts on the solutions to increasingly complex formulation needs, and how these can ensure quality and patient safety, while also decreasing time-to-market. Belinda Holdsworth, Strategic Growth Project Lead for DPS at Lonza, also emphasized how a robust visual inspection process which utilizes AI and automated robotics can greatly enhance process timelines. Read the full article here: https://lnkd.in/eds3Xnkw #AHealthierWorld #DrugProduct #LonzaDPS
-
-
Join us tomorrow to discover the commercial capabilities of the Lonza Small Molecules network and dive into a risk-based approach for process qualification of amorphous solid dispersions made by spray drying. In this insightful session, our experts will discuss the integration of process design and qualification into the broader process validation strategy. You'll learn how small-scale experiments can optimize drug substance usage and mitigate risks during the process qualification stage. We’ll also explore elements of product design, focusing on robust processes with built-in manufacturing flexibility. 💡 Real-world case studies will illustrate in-process hold times at full scale, providing practical examples of our methodologies in action. Register here: https://lnkd.in/dAM4k_Qe #LonzaSM
-
-
Kathrin joined Lonza in 2021, and works as an MSAT Expert for Drug Product Services at our site in Stein, Switzerland. "The daily dynamics of our work are determined by the diverse scientific knowledge and industry experiences that each team member contributes. Working at Lonza is an exciting journey as we continually realign with current market and customer needs. It offers me a variety of professional and personal opportunities to grow in my current role and if desired explore alternative career paths within the company." Read Kathrin's full story: https://lnkd.in/dCeKcrNE #AMeaningfulDifference #CareerGrowth #Opportunities #PharmaceuticalManufacturing
-
Verbundene Seiten
-
Lonza BioResearch Solutions
Biotechnologieforschung
Walkersville, Maryland
-
Lonza Capsules & Health Ingredients
Arzneimittelherstellung
Morristown, New Jersey
-
Lonza Testing Solutions
Biotechnologieforschung
Walkersville, Maryland
-
Lonza MODA®- Informatics Solutions for QC & Manufacturing
Softwareentwicklung
Basel, BS
Ähnliche Seiten
Finanzierung
Letzte Runde
Fremdkapital nach Börsengang444.795.339,00 $